U.S. Drug Spending Will Increase 7.6% in 2015, Including PCSK9 Costs – CMS
Agency expects PCSK9 drugs for cholesterol will have relatively “modest” impact on drug spending across commercial and government payers in 2015, actuaries explain.
Agency expects PCSK9 drugs for cholesterol will have relatively “modest” impact on drug spending across commercial and government payers in 2015, actuaries explain.